Bedfordshire and Luton Joint Formulary Formulary

Formulary items found

Status	Description	Section
RED	Baricitinib Olumiant^® ( 2mg and 4 mg tablets)	Infections, Antiviral drugs, 05.03
RED	Baricitinib 2mg, 4mg Olumiant^® (Tablets)	Musculoskeletal and joint diseases, Drugs which suppress the rheumatic disease process, 10.01.03
RED	Baricitinib 2mg, 4mg Olumiant^® (Tablets)	Musculoskeletal and joint diseases, Drugs which suppress the rheumatic disease process, 10.01.03
RED	Baricitinib Olumiant^® (2mg and 4mg f/c tablets)	Skin, Drugs affecting the immune response, 13.05.03

Links found

MHRA Drug Safety Update: Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors (August 2020)
MHRA Drug Safety Update: Baricitinib (Olumiant¥): increased risk of diverticulitis, particularly in patients with risk factors (August 2020)
MHRA Drug Safety Update: Baricitinib (Olumiant¥): risk of venous thromboembolism (March 2020)
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
NICE TA926: Baricitinib for treating severe alopecia areata (NOT RECOMMENDED)
NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (TERMINATED APPRAISAL)